<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975828</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-07-02</org_study_id>
    <nct_id>NCT04975828</nct_id>
  </id_info>
  <brief_title>Correlation Between Micro Vascular Complications and Severity of Coronary Artery Disease in Type 2 DM</brief_title>
  <official_title>Correlation Between Micro Vascular Complications and Severity of Coronary Artery Disease in Type 2 DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is a major cause of morbidity and mortality worldwide and it contributes&#xD;
      substantially to healthcare costs. Type 2 Diabetes mellitus is the most common type of&#xD;
      diabetes accounting for approximately (90%) of all cases.&#xD;
&#xD;
      Type 2 DM carries a two to six times risk of death from cardiovascular etiologies, such that&#xD;
      age adjusted prevalence of white Americans for coronary artery disease (CAD) is double in&#xD;
      those with type 2 DM than those without .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>correlation between microvascular complications and severity of coronary disease in type2 DM.</measure>
    <time_frame>4 months</time_frame>
    <description>outcome of study to assess correlation between coronary artery disease and microvascular complications in type 2 DM to early predict coronary artery disease in patient type 2 DM with microvascular complications by non invasive methods as stress ECG or CT coronary angio or cardiac MRI and prevent serious complications as myocardial infarction.&#xD;
assess microvascular complication as follow albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patients With Type 2 DM Who Underwent Coronary Angiography Due to Coronary Artery Disease and Presence of Microvascular Complications in Same Patients</condition>
  <arm_group>
    <arm_group_label>patients type 2 DM with coronary artery disease and diabetic retinopathy.</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients type 2 DM with coronary artery disease and diabetic neuropathy.</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients type 2 DM with coronary artery disease and diabetic nephropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patient type 2 DM with coronary artery disease and non microvascular complications.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>albumin creatinine ratio -EGFR-fundus examination- coronary angiography.</intervention_name>
    <description>albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.</description>
    <arm_group_label>patient type 2 DM with coronary artery disease and non microvascular complications.</arm_group_label>
    <arm_group_label>patients type 2 DM with coronary artery disease and diabetic nephropathy</arm_group_label>
    <arm_group_label>patients type 2 DM with coronary artery disease and diabetic neuropathy.</arm_group_label>
    <arm_group_label>patients type 2 DM with coronary artery disease and diabetic retinopathy.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study enrolled 100 patients known type 2 DM with coronary artery disease and coronary&#xD;
        angiography done to diagnosis coronary artery disease then assess microvascular&#xD;
        complications in those patients by fundus examination-neurologic examination-albumin&#xD;
        creatinine ratio-EGFR. IN STUDY investigator exclude any other cause can lead to&#xD;
        microvascular complications example hypertension.&#xD;
&#xD;
        aim of study to early predict coronary artery disease in patient with type 2 DM if&#xD;
        microvascular complication presenet by non invasive investigation as stress ECG.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        100 Cases were selected with type II (DM) patients who had been admitted for coronary&#xD;
        angiography because of suspected (CAD) to the Catheter lab unit of Sohag University&#xD;
        Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 DM.&#xD;
&#xD;
          2. Smoker.&#xD;
&#xD;
          3. Hypertension.&#xD;
&#xD;
          4. Pregnant women.&#xD;
&#xD;
          5. Patient known non diabetic retinal disease non diabetic. nephropathy or neuropathy.&#xD;
&#xD;
          6. History of familial dyslipidemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Islam k Fathy, resident</last_name>
    <phone>01011456295</phone>
    <email>islam.ali2@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adel A Elsayed, Professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Osama R Elsherief</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama R Elsherief, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Ybarra-Muñoz J, Jurado-Campos J, Garcia-Gil M, Zabaleta-Del-Olmo E, Mir-Coll T, Zabalegui A, Vidal J, Romeo JH. Cardiovascular disease predicts diabetic peripheral polyneuropathy in subjects with type 2 diabetes: A 10-year prospective study. Eur J Cardiovasc Nurs. 2016 Jun;15(4):248-54. doi: 10.1177/1474515114565215. Epub 2014 Dec 19.</citation>
    <PMID>25527522</PMID>
  </reference>
  <reference>
    <citation>Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JW. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019 Dec;26(2_suppl):25-32. doi: 10.1177/2047487319878371. Epub 2019 Nov 13. Review.</citation>
    <PMID>31722562</PMID>
  </reference>
  <reference>
    <citation>Glovaci D, Fan W, Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep. 2019 Mar 4;21(4):21. doi: 10.1007/s11886-019-1107-y. Review.</citation>
    <PMID>30828746</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Islam Khaled Fathy</investigator_full_name>
    <investigator_title>resident at internal medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

